Abbott (NYSE:ABT) is claiming a big win for its Amplatzer Amulet device in a head-to-head trial with Boston Scientific’s (NYSE:BSX) Watchman.
Late-breaking data presented at the European Society of Cardiology Congress and simultaneously published in Circulation support the FDA’s recent approval for the Amplatzer Amulet, Abbott said in a news release.
The Amplatzer Amulet Left Atrial Appendage (LAA) Occluder is a small pouch that connects to the upper left chamber of the heart to reduce ischemic stroke risk for people with atrial fibrillation (AFib).
The Abbott Park, Illinois-based medical device manufacturer said the results show its Amplatzer Amulet was superior for the primary endpoint of LAA closure and non-inferior for the primary endpoints of safety and effectiveness when compared to Boston Scientific’s Watchman.